CTIS2023-504303-86-00进行中（未招募）1 期
A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation - WO41535
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 668
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Participants with a first diagnosis of HCC who have undergone either curative resection or ablation (RFS or MWA only) within 4-12 weeks prior to randomization, High risk for HCC recurrence after resection or ablation, Full recovery from surgical resection or ablation within 4 weeks prior to randomization, Absence of MVI (Vp3 or Vp4), ECOG Performance Status of 0 or 1, Child-Pugh Class A status
排除标准
- •Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC, Evidence of residual, recurrent, or metastatic disease at randomization, On the waiting list for liver transplant, History of hepatic encephalopathy, Prior bleeding event due to untreated or incompletely treated esophageal and/or gastric varices within 6 months prior to randomization, Have received more than 1 cycle of adjuvant TACE following surgical resection
研究者
相似试验
已完成
3 期
A Phase III Study of Atezolizumab in Patients with 2L/3L Renal Cell CarcinomaJPRN-jRCT2080225357Chugai Pharmaceutical Co., Ltd.500
已完成
3 期
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblatioHepatocellular CarcinomaJPRN-jRCT2080224943Chugai Pharmaceutical Co., Ltd.662
进行中（未招募）
1 期
Efficacy and Safety Study of Gepotidacin in the Treatment of Uncomplicated Urogenital GonorrheaEUCTR2018-001780-23-DEGSK Research & Development Limited620
进行中（未招募）
1 期
Efficacy and Safety Study of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrheancomplicated Urogenital GonorrheaEUCTR2018-001780-23-GBGlaxoSmithKline Research & Development Limited628
进行中（未招募）
1 期
A study of a combination of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) compared to Bortezomib with Pomalidomide and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2018-004354-21-CZGlaxoSmithKline Research & Development Limited284